ABCL vs DBVT vs HALO vs REGN vs MRK

For growth investors, AbCellera Biologics Inc.

(ABCL) is the stronger pick with 160. 6% revenue growth year-over-year, versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 4x trailing P/E (21. 9x forward), making it the more compelling value choice. Analysts rate AbCellera Biologics Inc. (ABCL) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 4x versus Halozyme Therapeutics, Inc. at 25. 5x. On forward P/E, Halozyme Therapeutics, Inc. is actually cheaper at 8. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Halozyme Therapeutics, Inc. wins at 0. 35x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Merck & Co.

, Inc. (MRK) delivered a total return of +70. 2%, compared to -83. 4% for AbCellera Biologics Inc. (ABCL). Over 10 years, the gap is even starker: HALO returned +570. 7% versus ABCL's -91. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Merck & Co.

, Inc. (MRK) is the lower-risk stock at 0. 48β versus AbCellera Biologics Inc. 's 2. 31β — meaning ABCL is approximately 386% more volatile than MRK relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 96% for Merck & Co. , Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), AbCellera Biologics Inc.

(ABCL) is pulling ahead at 160. 6% versus 1. 0% for Regeneron Pharmaceuticals, Inc. (REGN). On earnings-per-share growth, the picture is similar: AbCellera Biologics Inc. grew EPS 10. 9% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, HALO leads at 28. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -194. 9% for AbCellera Biologics Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HALO leads at 58. 4% versus -289. 0% for ABCL. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Halozyme Therapeutics, Inc. (HALO) is the more undervalued stock at a PEG of 0. 35x versus Regeneron Pharmaceuticals, Inc. 's 2. 43x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Halozyme Therapeutics, Inc. (HALO) trades at 8. 1x forward P/E versus 21. 9x for Merck & Co. , Inc. — 13. 8x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ABCL: 318. 5% to $20. 17.

In this comparison, MRK (2.

9% yield), REGN (0. 5% yield) pay a dividend. ABCL, DBVT, HALO do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Merck & Co.

, Inc. (MRK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48), 2. 9% yield, +166. 5% 10Y return). AbCellera Biologics Inc. (ABCL) carries a higher beta of 2. 31 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MRK: +166. 5%, ABCL: -91. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ABCL is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; HALO is a small-cap high-growth stock; REGN is a mid-cap deep-value stock; MRK is a large-cap deep-value stock. MRK pays a dividend while ABCL, DBVT, HALO, REGN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.